Abstract
To assist international efforts to address major gaps in the availability and accessibility of quality diagnosis and treatment for multi-drug resistant tuberculosis, Médecins Sans Frontières has adapted an approach combining three sets of interlinked strategies: direct provision of medical care, operational research, and public health advocacy. The activities undertaken are reviewed each in turn, with stress on the ways that they impact upon and consolidate each other. In spite of new opportunities, including technologies which significantly improve diagnosis and new, more patient-centred approaches, a much broader international mobilization is needed in order to confront MDR-TB. It is also questionable as to whether existing technologies are successful enough to provide a solid basis for expanded national programs.
ProCite
RefWorks
Reference Manager
BibTeX
Zotero
EndNote
-
1. World Health Organisation 2011 World TB Report 2011 WHO Geneva.
-
2. World Health Organisation 2011 Towards universal access to diagnosis and treatment of multidrug-resistant and extensively drug-resistant tuberculosis by 2015 WHO Geneva.
-
3. In countries with more than 10 cases. World Health Organisation (2007): Multidrug and extensively drug-resistant TB (M/XDR-TB) 2010 Global Report on Surveillance and Response. WHO, Geneva. 7 p.
-
4. World Health Organisation 2011 World TB Report 2011 WHO Geneva.
-
5. WHO European Ministerial Forum 2007 The Berlin Declaration on Tuberculosis WHO Copenhagen.
-
6. World Health Organisation 2006 The Stop TB Strategy: Building on and enhancing DOTS to meet the TB-related Millennium Development Goals WHO Geneva.
-
7. Ministerial Meeting of High M/XDR-TB Burden Countries 2009 The Beijing “Call for Action’ on Tuberculosis Control and Patient Care: Together Addressing the Global M/XDRTB Epidemic WHO Geneva.
-
8. World Health Assembly 2009 WHA 62.15: Prevention and control of multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis WHO Geneva.
-
9. H.S. Cox S. Kalon S. Allamuratova V. Siziare Z. Tigay S. Ruesch-Gerdes K. Karimovich Y. Kebede C. Mills 2007 Multidrug-resistant Tuberculosis Treatment Outcomes in Karakalpakstan, Uzbekistan: Treatment Complexity and XDR-TB among Treatment Failures PLoS ONE 2 11 e1126.
-
10. J.C. Brust N.S. Shah M. Scott K. Chaiyachati M. Lygizos T.L. van der Merwe S. Bamber Z. Radebe M. Loveday A.P. Moll B. Margot U.G. Lalloo G.H. Friedland N.R. Gandhi 2012 Integrated, home-based treatment for MDR-TB and HIV in rural South Africa: an alternate model of care Int J Tuberc Lung Dis 16 8 998–1004.
-
11. Lalor MK , Allamuratova S, Althomsons S, Tiegay Z, Khamraev AK, Grieg J, Braker K, du Cros P, Telnov O: Risk factors associated with default from Multi Drug Resistant tuberculosis treatment, Uzbekistan, in patients enrolled between 2003–2008. Presentation at IUATLD conference (2011).
-
12. S. Majumdar D. O'Brien N. Hurtado C. Hewison P. du Cros 2011 The ‘frozen state’ of drug-resistant tuberculosis: notes from the field in Abkhazia Intern Med J 41 805–808.
-
13. H.S. Cox T. Kubica D. Doshetov Y. Kabede S. Ruesch-Gerdes S. Niemann 2005 The Beijing genotype and drug resistant tuberculosis in the Aral Sea region of Central Asia Respir Res 6 134.
-
14. M. Bonnet V. Sizaire Y. Kebede A. Janin D. Doshetov B. Mirzoian A. Arzumanian T. Muminov E. Iona L. Rigouts S. Rüsch-Gerdes F. Varaine 2005 Does one size fit all? Drug resistance and standard treatments: results of six tuberculosis programmes in former Soviet countries Int J Tuberc Lung Dis 9 1147–1154.
-
15. H.S. Cox J.D. Orozco R. Male S. Ruesch-Gerdes D. Falzon I. Small D. Doshetov Y. Kabede M. Aziz 2004 Multidrug-resistant tuberculosis in central Asia Emerg Infect Dis 10 865–872.
-
16. D. Balabanova B. Roberts E. Richardson C. Haerpfer M. McKee 2012 Health care reform in the former Soviet Union: Beyond the transition Health Serv Res 47 840–864.
-
17. World Health Organisation 2011 World TB Report 2011 WHO Geneva.
-
18. Médecins Sans Frontières 2011 Treating Drug-Resistant TB: What does it take? MSF London.
-
19. Working Group on New TB Drugs (2012): Drug Pipeline. [Internet.] Last accessed August 21, 2012 at http://www.newtbdrugs.org/pipeline.php.
Monthly Content Usage
| Abstract Views | Full Text Views | PDF Downloads | |
|---|---|---|---|
| Aug 2020 | 1 | 0 | 0 |
| Sep 2020 | 0 | 0 | 0 |
| Oct 2020 | 1 | 0 | 0 |
| Nov 2020 | 2 | 14 | 5 |
| Dec 2020 | 0 | 0 | 0 |
| Jan 2021 | 1 | 2 | 3 |
| Feb 2021 | 0 | 0 | 0 |
Copyright Akadémiai Kiadó
AKJournals is the trademark of Akadémiai Kiadó's journal publishing business branch.
Copyright Akadémiai Kiadó AKJournals is the trademark of Akadémiai Kiadó's journal publishing business branch.
Powered by PubFactory